Deoxythymidine kinase (TK) catalyzes the phosphorylation of deoxythymidine to deoxythymidine monophosphate, an essential precursor of DNA thymine. Among the different isoenzymes of TK (ATP: thymidine 5'-phosphotransferase (EC 2.7.1.21)) present in human cells, TK1, the cytosolar form of TK, occurs in large amounts in dividing cells and is more or less absent from resting differentiated cells (Bello et al., 1974) . The development of a TK assay optimized for TK1, utilizing [1251] iododeoxyuridine as substrate, has been found to facilitate the detection of normal serum TK (S-TK) levels (Gronowitz et al., 1984) . Elevated S-TK levels were observed in patients with different malignant diseases, such as chronic granulocytic leukaemia, acute myeloblastic leukemia (AML), acute lymphoblastic leukaemia (ALL), lung cancer of the small cell type, and nonHodgkin's lymphoma. The pretreatment S-TK level in patients with non-Hodgkin's lymphoma correlated both to clinical stage and to grade of malignancy. Higher values were consistently found in patients with advanced disease and histology (Gronowitz et al., 1983b) .
The aim of the present study was to investigate how the pretreatment level of S-TK correlated to the type of acute leukaemia, the remission rate and the duration of remission. (Bennet et al., 1976) aggregates in the bone marrow sections. Criteria for complete remission also included a response duration of more than one month. Maintenance therapy was started when the patients had attained complete remission. The AML patients received treatment every month for 36 months consisting of cytarabine 1 mg kg-1 x 1 i.v Days 1-5 together with either 6-thioguanine 1 mgm-2 p.o x 2 Days 1-5 or daunorubicin 1.5 mg kg-1 x 1 i.v Day 1, the latter two drugs given alternately. Patients who had received doxorubicin during induction of remission were also given doxorubicin 50 mg m-2 instead of daunorobicin during maintenance therapy. Daunorubicin or doxorubicin was withdrawn after one year of maintenance and replaced by 6-thioguanine. Twelve patients received more extensive maintenance therapy which also included azacytidine. Patients with partial remission, progressive disease or relapse were treated individually. Two patients with AML underwent a bone marrow transplantation while in complete remission. Both died shortly after the transplantation, one of graft-versus-host disease and the other of cytomegalovirus infection. One patient with AML in complete remission died of sepsis during maintenance therapy. The duration of remission was measured from the date of achievement of complete remission to the date of relapse or of the last follow-up, i.e. October 1983.
The enzyme assay system utilized 125I-IUdR (10-7M, 130-16OCimmol-1), as substrate and has been described in detail elsewhere (Gronowitz et al. 1984) . Under the conditions used, 1 unit of enzyme is equal to an anzyme activity of 1.2x 10-8 katal, and gives -I000cpm with the amount of isotope used. The average S-TK level in healthy subjects is estimated to be 2.4 units pM 1, with an upper limit of 5.0 units pl-1.
The data were analyzed by linear regression (r) and the Mann-Whitney test. All P values reported refer to two-sided tests. The variables S-TK, serum lactic dehydrogenase and the peripheral blast count were transformed into logarithmic scale before linear regression analysis. Remission duration was analyzed using the Cox's regression model (Cox, 1972) .
The pretreatment values for S-TK are plotted in Figure 1 . S-TK was increased (>5.0 units) before treatment in all but three cases. A significant correlation was found between S-TK and both peripheral blast cell count (r=0.61; P<0.0001) and the degree of leukaemic bone marrow infiltration (r=0.40; P<0.01). There was also a significant correlation between S-TK and serum lactic dehydrogenase (r=0.67; P<0.0001). The median S-TK value for the 54 patients with AML was 84 units 1l-and for the patients with ALL (Cox et al., 1972) , but the follow-up time is not yet sufficient to permit a firm conclusion. The patient with the highest level (3050unitsyl-1) required 6 induction courses before complete remission was achieved. His remission lasted only 3 months. Only one of the 9 evaluable ALL patients was resistant to therapy and among the eight patients who achieved complete remission two have relapsed. Induction of remission in patients with acute leukaemia demands hazardous treatment with cytostatic combinations. In spite of very intensive treatment, 20-30% of patients with AML and 10% of patients with ALL still fail to achieve complete remission (Lister et al., 1982) . It is possible that this group of patients may benefit from even more aggressive induction therapy, although the risk of therapy-related death may then increase considerably. There are many reports on analyses of correlations between the outcome of therapy and pretreatment variables. The improved supportive treatment has, however, made some of the previously reported factors such as thrombocytopenia, the presence of infectious complications and advanced age less important. With reduction in the failure of therapy due to inadequate supportive care, more attention has been focused on pretreatment variables that are more likely to reflect the inherent nature of the disease. Among these, chromosomal abnormalities (Nilsson et al., 1977) , a high serum lactic dehydrogenase level (Keating et al., 1980) and the presence of circulating immune complexes (Carpentier et al., 1982) have been reported to adversely affect the prognosis in AML. The FAB classification of AML does not seem to be of prognostic value . There are conflicting reports about the prognostic importance of the blast cell count (Passe et al., 1982 . In vitro growth characteristics of the leukaemic bone marrow cells seem to correlate with response to therapy (Spitzer et al., 1976) . The kinetics of the blast cell population has been extensively investigated, using the thymidine labeling index and flow cytofluorometric techniques to "tneasure the proportion of cells synthesizing DNA. Although a wide range of the percentage of cells in the S phase has been found, results concerning their prognostic value have been conflicting (Crowther et al., 1975 , Hart et al., 1977 , Dosik et al., 1980 , Sewell et al., 1981 . These methods are especially interesting for the present study, as TK is an enzyme with special preference for cells undergoing transition from the dormant to the dividing phase.
In this study we have shown that the pretreatment level of S-TK is elevated in almost all patients with acute leukaemia. Only 3/66 patients had normal values. Enhanced activity of TK in bone marrow has previously been found in patients with acute leukaemia (Nakao & Fugihoka 1968) . Recently, elevated levels of S-TK were reported in leukaemic mice and in a small number of patients with acute leukaemia (Kreis et al., 1982) . The cause of the enhanced levels of S-TK in acute leukaemia is not known. Widespread malignancies with a high blast count such as small cell carcinoma of the lung and non-Hodgkins lymphomas of unfavorable histology are also associated with high levels of S-TK (Gronowitz et al., 1983a) . In vitamin B12 deficiency, a disorder with a proliferating megaloblastic bone marrow with intramedullary haemolysis, very high activities of TK both in the bone marrow (Nakao et al., 1968) and in the serum (Hagberg et al., 1984) have been found. Thus it is possible that the high S-TK levels in acute leukaemia mirror the release of TK from malignant blasts cells. This release is probably dependent on the intracellular concentration, the degree of blastic destruction or leakage and the size of the tumor mass. The level of S-TK may be a product of these variables. In non-malignant leukocytosis or liver damage, S-TK is not elevated, while some viral disorders such as infectious mononucleosis give transiently high levels (Gronowitz et al., 1984) . We have also found that the pretreatment level of S-TK in AML correlates with the remission rate, with higher values in patients with therapy-resistant leukemia. The finding of S-TK as a prognostic factor in AML further corroborates previous observations in patients with non-Hodgkins lymphoma (Ellims et al., 1981a,b,c; Gronowitz et al., 1983) , where S-TK correlates to stage and histology, with higher values in more advanced disease and more aggressive histology (Gronowitz et al., 1983) . In chronic lymphocytic leukaemia (CLL) the S-TK level was found to be normal in patients with indolent disease and elevated in most of the patients with active disease . The elevation was, however, much lower than in the patients with acute leukaemia. It is difficult in this material to evaluate the importance of S-TK as a prognostic factor in comparison with other factors such as the level of peripheral blast cell count and the lactic dehydrogenase. Although this series of patients with acute leukaemia is too small to permit a definite conclusion as to the clinical usefulness of the S-TK assay, the results seem promising and warrant further investigations.
